Table 1.
Demographic and clinical characteristics for the full patient cohort and each treatment group: categorical variables
| Covariate | Levels | Total (N = 35) | Treatment Groups | |
|---|---|---|---|---|
| Entinostat + Lapatinib (N = 14) | Entinostat + Lapatinib + Trastuzumab (N = 21) | |||
| Sex | Female | 34 (97.1%) | 13 (38.2%) | 21 (61.8%) |
| Male | 1 (2.9%) | 1 (100%) | 0 (0%) | |
| Race/Ethnicity | Black | 5 (14.3%) | 1 (20%) | 4 (80%) |
| Hispanic | 6 (17.1%) | 4 (66.7%) | 2 (33.3%) | |
| White | 24 (68.6%) | 9 (37.5%) | 15 (62.5%) | |
| ER | Positive | 17 (48.6%) | 6 (35.3%) | 11 (64.7%) |
| Negative | 18 (51.4%) | 8 (44.4%) | 10 (55.6%) | |
| Negative | 25 (73.5%) | 10 (40%) | 15 (60%) | |
| PgR | Positive | 9 (26.5%) | 4 (44.4%) | 5 (55.6%) |
| Unknown | 1 (2.8%) | |||
| HER2 IHC | 3+ | 5 (100%) | 2 (40%) | 3 (60%) |
| Unknown | 30 (85.7%) | |||
| Histopathology | Inflammatory breast cancer | 13 (37.1%) | 6 (46.2%) | 7 (53.8%) |
| Invasive ductal carcinoma | 22 (62.9%) | 8 (36.4%) | 14 (63.6%) | |
| Previous anti-HER2 therapy | Trastuzumab* | 35 (100%) | 14 (100%) | 21 (100%) |
| Pertuzumab | 15 (42.9%) | 0 (0%) | 15 (100%) | |
| T-DM1 | 19 (54.3%) | 2 (10.5%) | 17 (89.5%) | |
| Lapatinib | 14 (40%) | 7 (50%) | 7 (50%) | |
| Metastatic Site | Bone | 4 (11.4%) | 0 (0%) | 4 (11.4%) |
| Chest wall | 5 (14.2%) | 1 (2.8%) | 4 (11.4%) | |
| Liver | 6 (17.1%) | 0 (0%) | 6 (17.1%) | |
| Lung | 7 (20%) | 0 (0%) | 7 (20%) | |
| Lymph nodes | 5 (14.2%) | 0 (0%) | 5 (14.2%) | |
| Pancreas | 1 (2.8%) | 0 (0%) | 1 (2.8%) | |
ER oestrogen receptor, PgR progesterone receptor, IHC immunohistochemistry, T-DM1 ado-trastuzumab emtansine. *All but 1 patient received prior trastuzumab, pertuzumab, T-DM1, and lapatinib in the metastatic setting. However, 1 patient received trastuzumab in the adjuvant setting; when the patient’s localised disease progressed to metastatic within 6 months, the patient enroled in the trial